comparemela.com
Home
Live Updates
ABIONYX Pharma: ABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury : comparemela.com
ABIONYX Pharma: ABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury
Top line results by late fall 2022 A potentially modifying effect on the progression of the inflammatory cascade in sepsis Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX eligible
Related Keywords
United States ,
Italy ,
Bari ,
Puglia ,
Loreto Gesualdo ,
Arthur Rouill ,
Nicolas Fossiez ,
Louis Victor Delouvrier ,
University Of Bari Aldo Moro ,
University Of Bari ,
Full Professor ,
Transplantation Unit ,
Bari Aldo Moro ,
Sequential Organ Failure Assessment ,
Victor Delouvrier ,
Abionyx ,
Dharma ,
Nnounces ,
Final ,
Patient ,
Enrollment ,
Hase ,
Linical ,
Trial ,
Treatment ,
Patients ,
Sepsis ,
Thigh ,
Risk ,
Developing ,
Cute ,
Kidney ,
Injury ,
comparemela.com © 2020. All Rights Reserved.